A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
A Phase 2 Randomized Open-Label Study of Neratinib Versus Lapatinib Plus Capecitabine For The Treatment Of ErbB-2 Positive Locally Advanced Or Metastatic Breast Cancer
This is a study of an experimental drug (neratinib) versus a combination of drugs (lapatinib and capecitabine) in women who have erbB-2 (HER-2) positive metastatic or locally advanced breast cancer. The goal of this study is to compare the two regimens in shrinking tumors and extending the lives of women with erbB2 (HER2) positive breast cancer. The study will also compare the safety of the two regimens and to compare quality of life of patients taking the two regimens.
Inclusion Criteria:
Exclusion Criteria:
Palm Springs, California 92262, United States
New York, New York 10065, United States
Oklahoma City, Oklahoma 73104, United States
Tyler, Texas 75701-2043, United States
Vienna, A-1090, Austria
Sofia, 1233, Bulgaria
Varna, 9000, Bulgaria
Québec, Quebec G1S 4L8, Canada
Hamburg, 20246, Germany
Heidelberg, 69120, Germany
Budapest, 1032, Hungary
Tokyo, Japan
Bialystok, 15-027, Poland
Pesochny, Sankt-Peterburg 197758, Russia
Ryazan, 390011, Russia
Ufa, 450054, Russia
Belgrade, 11000, Serbia
Oviedo, Principality of Asturias 33006, Spain
A Coruña, 15006, Spain
Valencia, 46010, Spain